The ALIVER Consortium announces positive results from Phase 2 equivalent trial of the novel liver dialysis device, Dialive
Safety of novel liver dialysis device confirmed
Liver failure patients in ICU treated with Dialive more likely to see organ failure resolved, and more quickly (p=0.03)
Significant improvements in mechanistic biomarkers of how Dialive improves organ function
7
th January 2021 - The
ALIVER Consortiumis pleased to announce positive data from the randomised controlled clinical trial of Dialive in adult patients with liver failure. The study found that twice as many patients with a history indicative of alcohol-related cirrhosis suffering from multiorgan failure, a condition referred to as acute-on-chronic liver failure (ACLF), recovered to having no organ failure when treated with the Dialive device compared to the control group.